SCP
KPTI icon

Syntal Capital Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Syntal Capital Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,860
Closed -$1.11M – 107
2020
Q1 		$1.11M Buy
+3,860
New +$1.06M 0.73% 46

Other funds holding KPTI

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Syntal Capital Partners's KPTI Position: Q2 2020 in Review

Syntal Capital Partners sold out of Karyopharm Therapeutics (KPTI) in Q2 2020, closing a stake of 3,860 shares — an estimated $1.11M sold.

Syntal Capital Partners first reported a position in KPTI in Q1 2020 and held it in 1 quarter. The position peaked at $1.11M in Q1 2020. 155 funds tracked by Wall St. Rank hold KPTI as of Q2 2020.

  • Syntal Capital Partners reported no remaining Karyopharm Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Syntal Capital Partners sold 3,860 Karyopharm Therapeutics shares in Q2 2020, an estimated $1.11M.
  • Syntal Capital Partners first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 1 quarter.
  • Syntal Capital Partners's Karyopharm Therapeutics position peaked at $1.11M in Q1 2020.
  • 155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2020.

Based on Syntal Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.